GB202108224D0 - Treatment - Google Patents

Treatment

Info

Publication number
GB202108224D0
GB202108224D0 GBGB2108224.3A GB202108224A GB202108224D0 GB 202108224 D0 GB202108224 D0 GB 202108224D0 GB 202108224 A GB202108224 A GB 202108224A GB 202108224 D0 GB202108224 D0 GB 202108224D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2108224.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healx Ltd
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Priority to GBGB2108224.3A priority Critical patent/GB202108224D0/en
Publication of GB202108224D0 publication Critical patent/GB202108224D0/en
Priority to BR112023025789A priority patent/BR112023025789A2/pt
Priority to CN202280040639.5A priority patent/CN117769419A/zh
Priority to CA3221964A priority patent/CA3221964A1/en
Priority to PCT/GB2022/051442 priority patent/WO2022258972A1/en
Priority to JP2023574531A priority patent/JP2024520690A/ja
Priority to KR1020247000745A priority patent/KR20240024175A/ko
Priority to EP22732622.0A priority patent/EP4351576A1/en
Priority to MX2023014530A priority patent/MX2023014530A/es
Priority to US18/567,829 priority patent/US20240261276A1/en
Priority to IL309177A priority patent/IL309177A/en
Priority to AU2022290019A priority patent/AU2022290019A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2108224.3A 2021-06-09 2021-06-09 Treatment Ceased GB202108224D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB2108224.3A GB202108224D0 (en) 2021-06-09 2021-06-09 Treatment
AU2022290019A AU2022290019A1 (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma
PCT/GB2022/051442 WO2022258972A1 (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma
CN202280040639.5A CN117769419A (zh) 2021-06-09 2022-06-09 用于在皮肤神经纤维瘤的治疗中使用的硝羟喹啉
CA3221964A CA3221964A1 (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma
BR112023025789A BR112023025789A2 (pt) 2021-06-09 2022-06-09 Nitroxolina para uso no tratamento de neurofibroma cutâneo
JP2023574531A JP2024520690A (ja) 2021-06-09 2022-06-09 皮膚神経線維腫の治療に使用するためのニトロキソリン
KR1020247000745A KR20240024175A (ko) 2021-06-09 2022-06-09 피부 신경섬유종의 치료에 사용하기 위한 니트록솔린
EP22732622.0A EP4351576A1 (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma
MX2023014530A MX2023014530A (es) 2021-06-09 2022-06-09 Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo.
US18/567,829 US20240261276A1 (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma
IL309177A IL309177A (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2108224.3A GB202108224D0 (en) 2021-06-09 2021-06-09 Treatment

Publications (1)

Publication Number Publication Date
GB202108224D0 true GB202108224D0 (en) 2021-07-21

Family

ID=76838879

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2108224.3A Ceased GB202108224D0 (en) 2021-06-09 2021-06-09 Treatment

Country Status (12)

Country Link
US (1) US20240261276A1 (https=)
EP (1) EP4351576A1 (https=)
JP (1) JP2024520690A (https=)
KR (1) KR20240024175A (https=)
CN (1) CN117769419A (https=)
AU (1) AU2022290019A1 (https=)
BR (1) BR112023025789A2 (https=)
CA (1) CA3221964A1 (https=)
GB (1) GB202108224D0 (https=)
IL (1) IL309177A (https=)
MX (1) MX2023014530A (https=)
WO (1) WO2022258972A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202116743D0 (en) * 2021-11-19 2022-01-05 Healx Ltd Treatment
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3039822C (en) * 2016-10-14 2026-02-17 Wake Forest University Health Sciences Compositions, cell constructs, and methods of making and using the same

Also Published As

Publication number Publication date
CN117769419A (zh) 2024-03-26
CA3221964A1 (en) 2022-12-15
EP4351576A1 (en) 2024-04-17
AU2022290019A1 (en) 2023-12-14
MX2023014530A (es) 2024-04-10
WO2022258972A1 (en) 2022-12-15
JP2024520690A (ja) 2024-05-24
BR112023025789A2 (pt) 2024-02-27
KR20240024175A (ko) 2024-02-23
US20240261276A1 (en) 2024-08-08
IL309177A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
IL312981A (en) care
GB202016058D0 (en) Therapeautic treatment
GB202116743D0 (en) Treatment
GB202108224D0 (en) Treatment
GB202103122D0 (en) Treatment
GB202003722D0 (en) Treatment
GB202018400D0 (en) Treatment
GB202002711D0 (en) Treatment
GB202006236D0 (en) New treatment
GB202114373D0 (en) Treatment
GB202109812D0 (en) Treatment
GB202109815D0 (en) Treatment
GB202104666D0 (en) COVID-19 treatment
GB202104416D0 (en) Treatment reginmens
GB202103957D0 (en) Treatment
GB202102488D0 (en) Treatment
GB202102410D0 (en) Treatment
GB202102366D0 (en) Treatment
GB202102373D0 (en) Treatment
GB202102369D0 (en) Treatment
GB202101897D0 (en) Treatment
GB202101875D0 (en) Treatment
GB202101212D0 (en) Treatment
GB202101210D0 (en) Treatment
GB202101213D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)